The role of IL-6 and STAT3 in inflammation and cancer

European Journal of Cancer

Volumn 41, Issue 16, 2005, Pages 2502-2512

  Hodge, David R ^a   Hurt, Elaine M ^b   Farrar, William L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

Author keywords

Cancer; IL 6; Inflammation; JAK; Kinase inhibitor; Resistance to chemotherapy; STATs

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; BORTEZOMIB; CYTOKINE; ERYTHROPOIETIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH HORMONE; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 9; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEASOME INHIBITOR; PROTEIN BCL 2; STAT1 PROTEIN; STAT3 PROTEIN; STAT5 PROTEIN; STAT5A PROTEIN; STAT5B PROTEIN; THROMBOPOIETIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; APOPTOSIS; B LYMPHOCYTE; BREAST CANCER; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CELL PROLIFERATION; CELL SURVIVAL; CELL TYPE; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; COLON CARCINOMA; HEAD AND NECK CARCINOMA; HUMAN; HUMAN HERPESVIRUS 8; INFLAMMATION; KIDNEY CANCER; KNOCKOUT MOUSE; LARGE GRANULAR LYMPHOCYTE; LIVER CELL CARCINOMA; LUNG CANCER; MELANOMA; MOUSE STRAIN; MULTIPLE MYELOMA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PLASMACYTOMA; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION; STOMACH CARCINOMA; T LYMPHOCYTE; UTERINE CERVIX CANCER;

EID: 27544476971     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2005.08.016     Document Type: Article

References (104)

1. L.M. Coussens, and Z. Werb Inflammation and cancer Nature 420 2002 860 867
2. P. Loetscher, M. Seitz, and I. Clark-Lewis Activation of NK cells by CC chemokines. Chemotaxis, Ca2+ mobilization, and enzyme release J Immunol 156 1996 322 327
3. A.A. Igonin, V.W. Armstrong, and M. Shipkova Circulating cytokines as markers of systemic inflammatory response in severe community-acquired pneumonia Clin Biochem 37 2004 204 209
4. A.I. Teplyakov, and E.V. Pryschepova Cytokines and soluble cell adhesion molecules. Possible markers of inflammatory response in atherosclerosis Ann NY Acad Sci 902 2000 320 322
5. J. Ma, T. Chen, and J. Mandelin Regulation of macrophage activation Cell Mol Life Sci 60 2003 2334 2346
6. H. Maeda, and T. Akaike Nitric oxide and oxygen radicals in infection, inflammation, and cancer Biochemistry (Moscow) 63 1998 854 865
7. P.B. Sehgal Cytokine-induced STAT signalling through the cytoplasmic compartment Adv Exp Med Biol 495 2001 161 168
8. C. Schindler, and I. Strehlow Cytokines and STAT signalling Adv Pharmacol 47 2000 113 174
9. K.D. Liu, S.L. Gaffen, and M.A. Goldsmith JAK/STAT signalling by cytokine receptors Curr Opin Immunol 10 1998 271 278
10. S.F. Soriano, A. Serrano, and P. Hernanz-Falcon Chemokines integrate JAK/STAT and G-protein pathways during chemotaxis and calcium flux responses Eur J Immunol 33 2003 1328 1333
11. E. Shacter, and S.A. Weitzman Chronic inflammation and cancer Oncology (Huntingt) 16 2002 217 226 229
12. X.H. Liu, A. Kirschenbaum, and M. Lu Prostaglandin E (2) stimulates prostatic intraepithelial neoplasia cell growth through activation of the interleukin-6/GP130/STAT-3 signalling pathway Biochem Biophys Res Commun 290 2002 249 255
13. M. Shinozaki, J. Hirahashi, and T. Lebedeva IL-15, a survival factor for kidney epithelial cells, counteracts apoptosis and inflammation during nephritis J Clin Invest 109 2002 951 960
14. A. Tourbah, C. Linnington, and C. Bachelin Inflammation promotes survival and migration of the CG4 oligodendrocyte progenitors transplanted in the spinal cord of both inflammatory and demyelinated EAE rats J Neurosci Res 50 1997 853 861
15. D.R. Hodge, W. Xiao, and L.H. Wang Activating mutations in STAT3 and STAT5 differentially affect cellular proliferation and apoptotic resistance in multiple myeloma cells Cancer Biol Ther 3 2004 188 194
16. M.A. Frassanito, A. Cusmai, and G. Iodice Autocrine interleukin-6 production and highly malignant multiple myeloma: relation with resistance to drug-induced apoptosis Blood 97 2001 483 489
17. T. Hideshima, N. Nakamura, and D. Chauhan Biologic sequelae of interleukin-6 induced PI3-K/Akt signalling in multiple myeloma Oncogene 20 2001 5991 6000
18. D. Kamimura, K. Ishihara, and T. Hirano IL-6 signal transduction and its physiological roles: the signal orchestration model Rev Physiol Biochem Pharmacol 149 2003 1 38
19. P.C. Heinrich, I. Behrmann, and G. Muller-Newen Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway Biochem J 334 Pt 2 1998 297 314
20. L.S. Steelman, S.C. Pohnert, and J.G. Shelton JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis Leukemia 18 2004 189 218
21. W.B. Ershler Interleukin-6: a cytokine for gerontologists J Am Geriatr Soc 41 1993 176 181
22. M.C. Wolvekamp, and R.L. Marquet Interleukin-6: historical background, genetics and biological significance Immunol Lett 24 1990 1 9
23. L. Yang, L. Wang, and H.K. Lin Interleukin-6 differentially regulates androgen receptor transactivation via PI3K-Akt, STAT3, and MAPK, three distinct signal pathways in prostate cancer cells Biochem Biophys Res Commun 305 2003 462 469
24. S. Miki, M. Iwano, and Y. Miki Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas FEBS Lett 250 1989 607 610
25. D. Eustace, X. Han, and R. Gooding Interleukin-6 (IL-6) functions as an autocrine growth factor in cervical carcinomas in vitro Gynecol Oncol 50 1993 15 19
26. N.J. Van Wagoner, J.W. Oh, and P. Repovic Interleukin-6 (IL-6) production by astrocytes: autocrine regulation by IL-6 and the soluble IL-6 receptor J Neurosci 19 1999 5236 5244
27. C.M. Leu, F.H. Wong, and C. Chang Interleukin-6 acts as an antiapoptotic factor in human esophageal carcinoma cells through the activation of both STAT3 and mitogen-activated protein kinase pathways Oncogene 22 2003 7809 7818
28. M. Okamoto, C. Lee, and R. Oyasu Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro Cancer Res 57 1997 141 146
29. A. Hammacher, L.D. Ward, and J. Weinstock Structure-function analysis of human IL-6: identification of two distinct regions that are important for receptor binding Protein Sci 3 1994 2280 2293
30. J.A. Lust, D.F. Jelinek, and K.A. Donovan Sequence, expression and function of an mRNA encoding a soluble form of the human interleukin-6 receptor (sIL-6R) Curr Top Microbiol Immunol 194 1995 199 206
31. T. Taga, and T. Kishimoto Role of a two-chain IL-6 receptor system in immune and hematopoietic cell regulation Crit Rev Immunol 11 1992 265 280
32. P. Autissier, J. De Vos, and J. Liautard Dimerization and activation of the common transducing chain (gp130) of the cytokines of the IL-6 family by mAb Int Immunol 10 1998 1881 1889
33. M. Suganuma, S. Okabe, and M. Kurusu Discrete roles of cytokines, TNF-alpha, IL-1, IL-6 in tumour promotion and cell transformation Int J Oncol 20 2002 131 136
34. J.E. Ayre Cervical cancer: chronic inflammation, stress and adaptation factors Acta Unio Int Contra Cancrum 12 1956 20 27
35. A.G. Dalgleish, and K.J. O'Byrne Chronic immune activation and inflammation in the pathogenesis of AIDS and cancer Adv Cancer Res 84 2002 231 276
36. B. Farrow, and B.M. Evers Inflammation and the development of pancreatic cancer Surg Oncol 10 2002 153 169
37. W.G. Nelson, A.M. De Marzo, and T.L. DeWeese The role of inflammation in the pathogenesis of prostate cancer J Urol 172 2004 S6 S11
38. P.M. Schwartsburd Chronic inflammation as inductor of pro-cancer microenvironment: pathogenesis of dysregulated feedback control Cancer Metastasis Rev 22 2003 95 102
39. F. Samaniego, S. Pati, and J. Karp Human herpesvirus 8 k1-associated nuclear factor-kappa b-dependent promoter activity: role in kaposi's sarcoma inflammation? J Natl Cancer Inst Monogr 2001 15 23
40. J. Osborne, P.S. Moore, and Y. Chang KSHV-encoded viral IL-6 activates multiple human IL-6 signalling pathways Hum Immunol 60 1999 921 927
41. M. Potter, M.D. Sklar, and W.P. Rowe Rapid viral induction of plasmacytomas in pristane-primed BALB-c mice Science 182 1973 592 594
42. M. Potter, and R.C. Maccardle Histology of developing plasma cell neoplasia induced by mineral oil in balb/c mice J Natl Cancer Inst 33 1964 497 515
43. M. Potter Plasma cell tumour-formation and antigen-binding myeloma proteins in mice Brit Med J 2 1971 320
44. K. Gado, S. Silva, and K. Paloczi Mouse plasmacytoma: an experimental model of human multiple myeloma Haematologica 86 2001 227 236
45. M. Potter, J.S. Wax, and A.O. Anderson Inhibition of plasmacytoma development in BALB/c mice by indomethacin J Exp Med 161 1985 996 1012
46. T. Nosaka, and T. Kitamura Janus kinases (JAKs) and signal transducers and activators of transcription (STATs) in hematopoietic cells Int J Hematol 71 2000 309 319
47. J. Yang, M. Chatterjee-Kishore, and S.M. Staugaitis Novel roles of unphosphorylated STAT3 in oncogenesis and transcriptional regulation Cancer Res 65 2005 939 947
48. J. Sasse, U. Hemmann, and C. Schwartz Mutational analysis of acute-phase response factor/Stat3 activation and dimerization Mol Cell Biol 17 1997 4677 4686
49. K. Takeda, and S. Akira STAT family of transcription factors in cytokine-mediated biological responses Cytokine Growth Factor Rev 11 2000 199 207
50. H.M. Seidel, L.H. Milocco, and P. Lamb Spacing of palindromic half sites as a determinant of selective STAT (signal transducers and activators of transcription) DNA binding and transcriptional activity Proc Natl Acad Sci USA 92 1995 3041 3045
51. T. Chen, L.H. Wang, and W.L. Farrar Interleukin 6 activates androgen receptor-mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCaP prostate cancer cells Cancer Res 60 2000 2132 2135
52. L.H. Wang, X.Y. Yang, and X. Zhang Transcriptional inactivation of STAT3 by PPARgamma suppresses IL-6-responsive multiple myeloma cells Immunity 20 2004 205 218
53. W.C. Stewart, J.E. Baugh Jr., and Z.E. Floyd STAT 5 activators can replace the requirement of FBS in the adipogenesis of cells Biochem Biophys Res Commun 324 2004 355 359
54. M. Baskiewicz-Masiuk, and B. Machalinski The role of the STAT5 proteins in the proliferation and apoptosis of the CML and AML cells Eur J Haematol 72 2004 420 429
55. J.F. Bromberg, M.H. Wrzeszczynska, and G. Devgan Stat3 as an oncogene Cell 98 1999 295 303
56. K. Ariyoshi, T. Nosaka, and K. Yamada Constitutive activation of STAT5 by a point mutation in the SH2 domain J Biol Chem 275 2000 24407 24413
57. B. Klein, K. Tarte, and M. Jourdan Survival and proliferation factors of normal and malignant plasma cells Int J Hematol 78 2003 106 113
58. A.L. Kovalchuk, J.S. Kim, and S.S. Park IL-6 transgenic mouse model for extraosseous plasmacytoma Proc Natl Acad Sci USA 99 2002 1509 1514
59. K. Ishihara, and T. Hirano IL-6 in autoimmune disease and chronic inflammatory proliferative disease Cytokine Growth Factor Rev 13 2002 357 368
60. E. Foti, G. Ferrandina, and R. Martucci IL-6, M-CSF and IAP cytokines in ovarian cancer: simultaneous assessment of serum levels Oncology 57 1999 211 215
61. M. Salem, O. Elbaz, and M. Zahran Malignancy: identification of predictors of disease status and progression in patients with myeloma (MM) Haematologica 5 2000 41 45
62. P.W. Thavasu, R.K. Ganjoo, and S.A. Maidment Multiple myeloma: an immunoclinical study of disease and response to treatment Hematol Oncol 13 1995 69 82
63. S.S. Makarov, W.N. Johnston, and J.C. Olsen NF-kappa B as a target for anti-inflammatory gene therapy: suppression of inflammatory responses in monocytic and stromal cells by stable gene transfer of I kappa B alpha cDNA Gene Ther 4 1997 846 852
64. D. Chauhan, H. Uchiyama, and Y. Akbarali Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B Blood 87 1996 1104 1112
65. P.A. Croonquist, M.A. Linden, and F. Zhao Gene profiling of a myeloma cell line reveals similarities and unique signatures among IL-6 response, N-ras-activating mutations, and coculture with bone marrow stromal cells Blood 102 2003 2581 2592
66. D. Puthier, S. Derenne, and S. Barille Mcl-1 and Bcl-xL are co-regulated by IL-6 in human myeloma cells Brit J Haematol 107 1999 392 395
67. H. Spets, T. Stromberg, and P. Georgii-Hemming Expression of the bcl-2 family of pro- and anti-apoptotic genes in multiple myeloma and normal plasma cells: regulation during interleukin-6 (IL-6)-induced growth and survival Eur J Haematol 69 2002 76 89
68. L. Song, Y. Li, and Y.X. Sun IL-6 inhibits apoptosis of human myeloma cell line XG-7 through activation of JAK/STAT pathway and up-regulation of Mcl-1 Ai Zheng 21 2002 113 116
69. L. Song, Y. Li, and Y. Sun Mcl-1 mediates cytokine deprivation induced apoptosis of human myeloma cell line XG-7 Chinese Med J (Engl) 115 2002 1241 1243
70. A.A. Chanan-Khan Bcl-2 antisense therapy in multiple myeloma Oncology (Huntingt) 18 2004 21 24
71. L. Quintanilla-Martinez, M. Kremer, and K. Specht Analysis of signal transducer and activator of transcription 3 (Stat 3) pathway in multiple myeloma: Stat 3 activation and cyclin D1 dysregulation are mutually exclusive events Am J Pathol 162 2003 1449 1461
72. Q. Zhang, P.N. Raghunath, and E. Vonderheid Lack of phosphotyrosine phosphatase SHP-1 expression in malignant T-cell lymphoma cells results from methylation of the SHP-1 promoter Am J Pathol 157 2000 1137 1146
73. O. Galm, H. Yoshikawa, and M. Esteller SOCS-1, a negative regulator of cytokine signalling, is frequently silenced by methylation in multiple myeloma Blood 101 2003 2784 2788
74. S. Depil, A. Saudemont, and B. Quesnel SOCS-1 gene methylation is frequent but does not appear to have prognostic value in patients with multiple myeloma Leukemia 17 2003 1678 1679
75. D. Chauhan, H. Uchiyama, and Y. Akbarali Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B Blood 87 1996 1104 1112
76. T. Hideshima, D. Chauhan, and T. Hayashi Proteasome inhibitor PS-341 abrogates IL-6 triggered signalling cascades via caspase-dependent downregulation of gp130 in multiple myeloma Oncogene 22 2003 8386 8393
77. D. Chauhan, G. Li, and K. Podar The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance Blood 103 2004 3158 3166
78. R. Starr, and D.J. Hilton Negative regulation of the JAK/STAT pathway Bioessays 21 1999 47 52
79. A. Yoshimura The CIS family: negative regulators of JAK-STAT signalling Cytokine Growth Factor Rev 9 1998 197 204
80. H. Yoshikawa, K. Matsubara, and G.S. Qian SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity Nat Genet 28 2001 29 35
81. A.M. Jimenez-Lara, M.J. Heine, and H. Gronemeyer PIAS3 (protein inhibitor of activated STAT-3) modulates the transcriptional activation mediated by the nuclear receptor coactivator TIF2 FEBS Lett 526 2002 142 146
82. F. Schaper, C. Gendo, and M. Eck Activation of the protein tyrosine phosphatase SHP2 via the interleukin-6 signal transducing receptor protein gp130 requires tyrosine kinase Jak1 and limits acute-phase protein expression Biochem J 335 Pt 3 1998 557 565
83. M. Weidler, J. Rether, and T. Anke Inhibition of interleukin-6 signalling and Stat3 activation by a new class of bioactive cyclopentenone derivatives Biochem Biophys Res Commun 276 2000 447 453
84. S. Mitsuhashi, H. Shima, and N. Tanuma Protein phosphatase type 2A, PP2A, is involved in degradation of gp130 Mol Cell Biochem 269 2005 183 187
85. N. Tanuma, H. Shima, and K. Nakamura Protein tyrosine phosphatase epsilonC selectively inhibits interleukin-6- and interleukin- 10-induced JAK-STAT signalling Blood 98 2001 3030 3034
86. D. Honemann, M. Chatterjee, and R. Savino The IL-6 receptor antagonist SANT-7 overcomes bone marrow stromal cell-mediated drug resistance of multiple myeloma cells Int J Cancer 93 2001 674 680
87. I. Imazeki, H. Saito, and M. Hasegawa IL-7 functions in cynomolgus monkeys blocked by a humanized antibody to human IL-6 receptor Int J Immunopharmacol 20 1998 345 357
88. Y.W. Huang, and E.S. Vitetta A monoclonal anti-human IL-6 receptor antibody inhibits the proliferation of human myeloma cells Hybridoma 12 1993 621 630
89. K. Yoshizaki, N. Nishimoto, and M. Mihara Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with a humanized anti-IL-6 receptor antibody Springer Semin Immunopathol 20 1998 247 259
90. L.H. Wang, R.A. Kirken, and R.A. Erwin JAK3, STAT, and MAPK signalling pathways as novel molecular targets for the tyrphostin AG-490 regulation of IL-2-mediated T cell response J Immunol 162 1999 3897 3904
91. M.A. Blaskovich, J. Sun, and A. Cantor Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signalling pathway inhibitor with potent antitumour activity against human and murine cancer cells in mice Cancer Res 63 2003 1270 1279
92. R. Malaviya, D. Zhu, and I. Dibirdik Targeting Janus kinase 3 in mast cells prevents immediate hypersensitivity reactions and anaphylaxis J Biol Chem 274 1999 27028 27038
93. H.M. Amin, L.J. Medeiros, and Y. Ma Inhibition of JAK3 induces apoptosis and decreases anaplastic lymphoma kinase activity in anaplastic large cell lymphoma Oncogene 22 2003 5399 5407
94. K. Nagel-Wolfrum, C. Buerger, and I. Wittig The interaction of specific peptide aptamers with the DNA binding domain and the dimerization domain of the transcription factor Stat3 inhibits transactivation and induces apoptosis in tumour cells Mol Cancer Res 2 2004 170 182
95. C. Buerger, K. Nagel-Wolfrum, and C. Kunz Sequence-specific peptide aptamers, interacting with the intracellular domain of the epidermal growth factor receptor, interfere with Stat3 activation and inhibit the growth of tumour cells J Biol Chem 278 2003 37610 37621
96. L.O. Flowers, P.S. Subramaniam, and H.M. Johnson A SOCS-1 peptide mimetic inhibits both constitutive and IL-6 induced activation of STAT3 in prostate cancer cells Oncogene 24 2005 2114 2120
97. M. Carballo, M. Conde, and R. El Bekay Oxidative stress triggers STAT3 tyrosine phosphorylation and nuclear translocation in human lymphocytes J Biol Chem 274 1999 17580 17586
98. S. Ramanathan, S. Pooyan, and S. Stein Targeting the sodium-dependent multivitamin transporter (SMVT) for improving the oral absorption properties of a retro-inverso Tat nonapeptide Pharm Res 18 2001 950 956
99. A. Ricouart, A. Tartar, and C. Sergheraert Inhibition of protein kinase C by retro-inverso pseudosubstrate analogues Biochem Biophys Res Commun 165 1989 1382 1390
100. M. Zhao, H.K. Kleinman, and M. Mokotoff Synthesis and activity of partial retro-inverso analogs of the antimetastatic laminin-derived peptide, YIGSR-NH2 J Pept Res 49 1997 240 253
101. L.H. Wang, X.Y. Yang, and R.A. Kirken Targeted disruption of stat6 DNA binding activity by an oligonucleotide decoy blocks IL-4-driven T (H)2 cell response Blood 95 2000 1249 1257
102. L.H. Wang, X.Y. Yang, and X. Zhang The cis decoy against the estrogen response element suppresses breast cancer cells via target disrupting c-fos not mitogen-activated protein kinase activity Cancer Res 63 2003 2046 2051
103. T. Yamamoto, S. Hsu, and J. Lewis Green tea polyphenol causes differential oxidative environments in tumour versus normal epithelial cells J Pharmacol Exp Ther 307 2003 230 236
104. M.Z. Fang, Y. Wang, and N. Ai Tea polyphenol (-)-epigallocatechin-3- gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines Cancer Res 63 2003 7563 7570